Intellia Therapeutics Stock Alert: Securities Investigation on Behalf of Intellia Investors - Contact Kehoe Law Firm, P.C. - NTLA
October 27, 2025 9:41 AM EDT | Source: Kehoe Law Firm, P.C.
Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia") (NASDAQ: NTLA).
On October 27, 2025, Intellia reported that ". . . it has temporarily paused dosing and screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran ('nex-z')."
Intellia stated that "[t]his action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial's protocol-defined pausing criteria."
On this news, Intellia's stock price dropped more than 45% in pre-market trading on October 27, 2025.
Investors of Intellia stock with financial losses are encouraged to complete Kehoe Law Firm's Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.
Additional information is available at https://kehoelawfirm.com/intellia-therapeutics-ntla/.
ABOUT KEHOE LAW FIRM, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.
Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.
This press release may constitute attorney advertising.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272033
